Dear Well-Wishers,

Greetings from Oviya MedSafe!

I am excited to begin this September 2016 edition of Oviya MedSafe’s newsletter with the fact that our hometown Coimbatore has been adjudged the Best Corporation among 100 cities in India by a Gurgaon-based independent thinktank named Skoch that deals with socio-economic issues with a focus on inclusive growth. The award was presented to Dr K Vijaya Karthikeyan, the Commissioner of Coimbatore Corporation, at the 45th Skoch Summit held in Hyderabad on 09-Sep-2016. While I personally am not surprised at this long overdue recognition for the city, it is indeed a moment of pride for all of us at Oviya MedSafe. This award, along with the three platinum awards and the orders of merit for different projects, rightly positions to the outside world the vibrance of Coimbatore as a business destination with state-of-the-art infrastructure.

September 2016 would rightly go down in my diary as a month of special significance in my professional life, thanks to the opportunity I had to share the dais with Dr G N Singh, the Drug Controller General of India (DCGI) and Prof Dr N K Ganguly, former Director General of the Indian Council of Medical Research (ICMR), during the inauguration of the 3rd National Pharmacovigilance Symposium of the Indian Society for Clinical Research. While I was actively involved in the symposium as the Chair of ISCR’s Pharmacovigilance Council, Oviya MedSafe was a proud sponsor of the symposium which had the theme “Evolving a Pharmacovigilant Environment in India – Collaborations, Opportunities & Challenges”. True to the theme, the symposium brought together pharmacovigilance stakeholders from the pharmaceutical industry, contract research organizations, pharmacovigilance service providers, healthcare professionals, academia and regulators on a common platform to deliberate on the evolution of a pharmacovigilant environment in India by facilitating collaborative efforts to aid the emerging regulatory initiatives.

Apart from delivering the welcome address, I was also invited to speak on the topic “Pharmacovigilance as a value addition for the Pharmaceutical Industry in contemporary Indian scenario”, which was well-received and went on to stimulate intense interaction among the audience. I positioned that pharmacovigilance, beyond fulfilling its role as a regulatory exercise targeting to achieve the humanitarian/ethical aim of patient safety, adds definitive value to the pharmaceutical industry by enhancing corporate image, ensuring financial security, envisioning scientific challenges and enabling business expansion. Since many of the participants requested me to share my slide deck with them, I further revised it to make it relevant not only to the Indian scenario but the global scenario as well. Please feel free to download the slide deck from Oviya MedSafe’s Downloads Page.

The news about this symposium was featured in Express Pharma and Pharmabiz. Some pictures clicked at this event (as well as most of our important past events) have been uploaded on Oviya MedSafe’s Gallery Page.

Before signing off, I would like to take the pleasure of announcing that Oviya MedSafe has collaborated with VHEO Ventures (an event management firm based in Coimbatore) to conduct focused hands-on training workshops for pharmacovigilance stakeholders in India, in order to empower them to such an extent that they will be able to understand and comply with the applicable regulations (both in India and abroad), either by performing the pharmacovigilance activities by themselves or by delegating their responsibilities to Oviya MedSafe. This workshop is being planned at Chennai, preferably on 02-Dec-2016. More details will follow shortly.

Thanking you for all of your interest and looking forward to meeting you through our October 2016 newsletter edition,

With thanks & regards,
Dr J Vijay Venkatraman

Managing Director & CEO,
Oviya MedSafe Pvt Ltd,
Coimbatore, India
Phone: +91-422-2444442

Oviya MedSafe UK Ltd,
London, UK
Phone: +44-8452-733839

Follow us on: FacebookGoogle PlusLinkedIn & Twitter

Leave a comment

Your email address will not be published. Required fields are marked *